Patents by Inventor Yi Yu

Yi Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12787485
    Abstract: In one aspect, a method for manufacturing a solar cell includes: manufacturing a barrier layer on a transparent conductive film of a solar cell wafer; manufacturing a first copper seed layer on the barrier layer by a chemical copper plating method; manufacturing a second copper seed layer on the first copper seed layer by a sputtering method; and manufacturing a grid line electrode on the second copper seed layer.
    Type: Grant
    Filed: May 30, 2023
    Date of Patent: November 3, 2026
    Assignee: TONGWEI SOLAR (CHENGDU) CO., LTD.
    Inventors: Kesheng Wei, Yi Yu, Jin Wang, Lei Xu
  • Patent number: 12767959
    Abstract: The invention features nucleobase editors and multi-effector nucleobase editors having an improved editing profile with minimal off-target deamination, compositions comprising such editors, and methods of using the same to generate modifications in target nucleobase sequences.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: October 20, 2026
    Assignee: BEAM THERAPEUTICS INC.
    Inventors: Nicole Gaudelli, Yi Yu, Ian Slaymaker, Jason Michael Gehrke, Seung-Joo Lee, David A. Born
  • Patent number: 12767677
    Abstract: Disclosed are lithium difluoro-bis(oxalate)phosphate, a preparation method therefor, and an application thereof. The preparation method comprises the following steps: (1) mixing oxalyl chloride and lithium hexafluorophosphate with a nonaqueous solvent, adding siloxane, and reacting to obtain a lithium difluoro-bis(oxalate)phosphate solution; and (2) adding a poor solvent into the lithium difluoro-bis(oxalate)phosphate solution for crystallization treatment to obtain the lithium difluoro-bis(oxalate)phosphate. According to the present application, raw materials such as lithium hexafluorophosphate, oxalyl chloride, and hexamethyldisiloxane are used for preparing the difluoro-bis(oxalate)phosphate, and the method of the present application is few in side reaction, few in impurities, high in product purity, and suitable for industrial production.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: October 20, 2026
    Assignee: SHENZHEN YANYI NEW MATERIALS CO., LTD.
    Inventors: Min Yue, Yi Yu
  • Publication number: 20260256848
    Abstract: The present invention features compositions and methods for editing deleterious mutations associated with alpha-1 anti-trypsin (A1AT) deficiency. In particular embodiments, the invention provides methods for correcting mutations in an A1AT polynucleotide using an adenosine deaminase base editor, ABE8, having unprecedented levels of efficiency.
    Type: Application
    Filed: February 6, 2026
    Publication date: September 3, 2026
    Applicant: Beam Therapeutics Inc.
    Inventors: Nicole GAUDELLI, Michael PACKER, Bernd ZETSCHE, Ian SLAYMAKER, Yi YU, David A. BORN, Seung-Joo LEE
  • Publication number: 20260254186
    Abstract: An optical system includes a nanocavity having at least one nanostructure shaped to provide sub-wavelength confinement of an electromagnetic optical field. The nanocavity is shaped and formed to host a bound state in the continuum to provide spatial concentration and temporal storage of the electromagnetic optical field at the at least one nanostructure via an eigenmode of the electromagnetic optical field in the nanocavity. A method is for processing an electromagnetic optical field.
    Type: Application
    Filed: March 6, 2024
    Publication date: August 27, 2026
    Inventors: Yi YU, Jesper MORK
  • Publication number: 20260224748
    Abstract: Compositions and methods for editing deleterious mutations associated with Alpha-1 Antitrypsin Deficiency (A1AD). In particular embodiments, the invention provides methods for treating A1AD using a modified adenosine base editor with improved on-target editing and decreased off-target editing to correct mutations associated with A1AD.
    Type: Application
    Filed: April 16, 2026
    Publication date: August 6, 2026
    Applicant: Beam Therapeutics Inc.
    Inventors: Michael Packer, Brian Cafferty, Yi Yu
  • Patent number: 12699451
    Abstract: Provided are a method, apparatus, computer device, and storage medium for music recommendation based on a wearable device, and relates to the field of computer technologies. The method for music recommendation includes: obtaining one or more physiological parameters of a target user collected by the wearable device; inputting the one or more physiological parameters of the target user into a trained relaxation state assessment model to determine a current relaxation state of the target user; and determining at least one piece of target recommendation music based on at least one of the current relaxation state of the target user or relaxation parameters corresponding to multiple pieces of music to be recommended, wherein the at least one piece of target recommendation music is configured to be played for the target user.
    Type: Grant
    Filed: January 25, 2024
    Date of Patent: August 4, 2026
    Assignee: Anhui Huami Health Technology Co., Ltd.
    Inventors: Kongqiao Wang, Yi Yu, Guokang Zhu, Cong Zhang, Zi Meng
  • Publication number: 20260209746
    Abstract: The invention features base editors having reduced non-target deamination, methods of using the base editors, and assays for characterizing base editors as having decreased non-target deamination, e.g. compared to programmed, on-target deamination.
    Type: Application
    Filed: November 20, 2025
    Publication date: July 23, 2026
    Applicant: Beam Therapeutics Inc.
    Inventors: Ian Slaymaker, Jason Michael Gehrke, Nicole Gaudelli, Yi Yu
  • Publication number: 20260193645
    Abstract: Compositions and methods for treating phenylketonuria by introducing one or more alterations into a phenylalanine hydroxylase (PAH) polynucleotide in a cell. In particular embodiments, the disclosure provides a base editor system (e.g., a fusion protein or complex comprising a programable DNA binding protein, a nucleobase editor, and gRNA) for modifying a PAH polynucleotide, where the alteration is associated with an increase in the level or activity of a PAH polypeptide encoded by the polynucleotide.
    Type: Application
    Filed: March 4, 2026
    Publication date: July 9, 2026
    Applicant: Beam Therapeutics Inc.
    Inventors: Tanggis Bohnuud, Mandy Sze Lee, Yi Yu
  • Publication number: 20260182075
    Abstract: In one aspect, a method for manufacturing a solar cell includes: manufacturing a barrier layer on a transparent conductive film of a solar cell wafer; manufacturing a first copper seed layer on the barrier layer by a chemical copper plating method; manufacturing a second copper seed layer on the first copper seed layer by a sputtering method; and manufacturing a grid line electrode on the second copper seed layer.
    Type: Application
    Filed: May 30, 2023
    Publication date: June 25, 2026
    Inventors: Kesheng WEI, Yi YU, Jin WANG, Lei XU
  • Publication number: 20260176635
    Abstract: The present invention features genetically modified immune cells comprising novel adenosine base editors (e.g., ABE8) having enhanced anti-neoplasia activity, resistance to immune suppression, and decreased risk of eliciting a graft-versus-host reaction or host-versus-graft reaction, or a combination thereof. The present invention also features methods for producing and using these modified immune effector cells.
    Type: Application
    Filed: February 27, 2026
    Publication date: June 25, 2026
    Applicant: Beam Therapeutics Inc.
    Inventors: Nicole GAUDELLI, Michael PACKER, Ian SLAYMAKER, Yi YU, Bernd ZETSCHE, David A. BORN, Seung-Joo LEE, Jason M. GEHRKE
  • Patent number: 12664503
    Abstract: A data processing method includes: receiving a first service request initiated by a target account, an associated account corresponding to the target account initiating a second service request; constructing a homogeneous graph and a heterogeneous graph according to attribute data; performing community discovery processing on the homogeneous graph to obtain an attribute label of the first service request; performing node sequence sampling on the homogeneous graph and the heterogeneous graph to obtain a graph association feature vector corresponding to the first service request; and performing risk prediction based on the attribute label, the graph association feature vector and a behavior feature corresponding to the first attribute data, to obtain a risk prediction result.
    Type: Grant
    Filed: May 19, 2023
    Date of Patent: June 23, 2026
    Assignee: Tencent Cloud Computing (Beijing) Co., Ltd.
    Inventor: Yi Yu
  • Publication number: 20260170206
    Abstract: A reconfigurable 3D chip and an integration method thereof are provided. The method includes: designing the architecture of the reconfigurable 3D chip; performing semiconductor manufacturing on a reconfigurable computing logic chip of the reconfigurable 3D chip to obtain, an uncut reconfigurable logic wafer; according to the architecture of the reconfigurable 3D chip, bonding a reconfigurable logic wafer and a memory wafer together in a face-to-face manner by adopting a hybrid technology, and connecting a signal IO of the reconfigurable logic wafer and a signal IO of the memory wafer together; cutting the bonded and stacked chip to obtain an independent stacked die; and packaging the stacked die to obtain the reconfigurable 3D chip.
    Type: Application
    Filed: July 18, 2023
    Publication date: June 18, 2026
    Inventors: Peng Ouyang, Yi Yu
  • Publication number: 20260151508
    Abstract: Compositions and methods for editing deleterious mutations associated with Alpha-1 Antitrypsin Deficiency (A1AD). In particular embodiments, the invention provides methods for treating A1AD using a modified adenosine base editor with improved on-target editing and decreased off-target editing to correct mutations associated with A1AD.
    Type: Application
    Filed: December 11, 2025
    Publication date: June 4, 2026
    Applicant: Beam Therapeutics Inc.
    Inventors: Michael Packer, Brian Cafferty, Yi Yu
  • Patent number: 12622931
    Abstract: The present invention features compositions and methods for editing deleterious mutations associated with alpha-1 anti-trypsin (A1AT) deficiency. In particular embodiments, the invention provides methods for correcting mutations in an A1AT polynucleotide using an adenosine deaminase base editor. ABE8, having unprecedented levels of efficiency.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: May 12, 2026
    Assignee: BEAM THERAPEUTICS INC.
    Inventors: Nicole Gaudelli, Michael Packer, Bernd Zetsche, Ian Slaymaker, Yi Yu, David A. Born, Seung-Joo Lee
  • Patent number: 12612618
    Abstract: The invention features base editors having reduced non-target deamination, methods of using the base editors, and assays for characterizing base editors as having decreased non-target deamination, e.g. compared to programmed, on-target deamination.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: April 28, 2026
    Assignee: Beam Therapeutics Inc.
    Inventors: Ian Slaymaker, Jason Michael Gehrke, Nicole Gaudelli, Yi Yu
  • Publication number: 20260108590
    Abstract: The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.
    Type: Application
    Filed: October 29, 2025
    Publication date: April 23, 2026
    Applicant: Beam Therapeutics Inc.
    Inventors: Ian Slaymaker, Nicole Gaudelli, Yi Yu, Bernd Zetsche, David A. Born, Seung-Joo Lee, Michael Packer
  • Patent number: 12600971
    Abstract: The present invention features genetically modified immune cells comprising novel adenosine base editors (e.g., ABE8) having enhanced anti-neoplasia activity, resistance to immune suppression, and decreased risk of eliciting a graft-versus-host reaction or host-versus-graft reaction, or a combination thereof. The present invention also features methods for producing and using these modified immune effector cells.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: April 14, 2026
    Assignee: BEAM THERAPEUTICS INC.
    Inventors: Nicole Gaudelli, Michael Packer, Ian Slaymaker, Yi Yu, Bernd Zetsche, David A. Born, Seung-Joo Lee, Jason M. Gehrke
  • Publication number: 20260061041
    Abstract: The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.
    Type: Application
    Filed: November 14, 2025
    Publication date: March 5, 2026
    Applicant: Beam Therapeutics Inc.
    Inventors: Ian Slaymaker, Nicole Gaudelli, Yi Yu, Bernd Zetsche, David A. Born, Seung-Joo Lee, Michael Packer
  • Publication number: 20260025001
    Abstract: A control method includes performing multi-level classification processing on distributed energy resources to obtain corresponding power supply equipment, power storage equipment, and hybrid equipment, analyzing and processing power distribution data and load data in the smart grid to obtain a power distribution demand of the smart grid, and dividing the smart grid into different division areas, determining corresponding power supply equipment, power storage equipment, or hybrid equipment in accordance with the power distribution demand and the division areas, and performing storage regulation and control on the corresponding power supply equipment, power storage equipment, or hybrid equipment, and if it is determined that the power supply equipment, power storage equipment, or hybrid equipment has a manner of multi-resource participation in the storage regulation and control, adding different multi-resource participation pricing strategies for power supply equipment, power storage equipment, or hybrid equipm
    Type: Application
    Filed: July 17, 2024
    Publication date: January 22, 2026
    Inventors: GANG SUN, XIAO YANG, YULING CHEN, SHIJUN CHEN, JUNDA MA, CHUNGUANG LU, ZHONGHE HONG, RAN SHEN, PENGFEI LU, CHI JIANG, JIALI YU, RONGGUO HUANG, LINNA NI, JIAYING WANG, YI YU, YUHAO CHEN